At a glance
ClinicalIndex Comparison RecordN/ACompleted· 258 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Study Evaluating the Probability of OncotypeDx to Allocate At Low or High Risk of Recurrence Early ER Positive HER2 Negative Breast Cancer Patients with Uncertain Biological Behavior Evaluated by Pathological Parameters
In Brief
An observational study for Breast Cancer. Completed, enrolled 258 participants across 1 site.
Detailed Summary
In some cases of hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative early breast cancer the benefit of adding adjuvant chemotherapy to hormonal treatment, estimated on the basis of the classical clinico-pathological parameters, is unclear. In these cases the application of a genomic test could be useful in guiding the therapeutic choice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesItaly
CollaboratorsGenomic Health®, Inc., Istituto Toscano Tumori
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
Primary CompletionMay 2021
First PostedApr 2024
Study CompletionDec 2024
TodayJul 2026
First PostedApr 12, 2024
Enrollment StartMar 8, 2018
Primary CompletionMay 15, 2021
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 2.2 years ago